Blog Baltimore: UMB Licenses Technology to Y Combinator-backed Biotech Startup

A biotech startup that’s backed by Silicon Valley’s well-known Y Combinator accelerator has ties to Baltimore: GEn1E Lifesciences is working to commercialize a treatment for inflammatory and age-related diseases that was developed at the University of Maryland, Baltimore, and is partnering with a Baltimore-based startup that also grew out of UMB collaboration.

On Tuesday, UMB said it granted GEn1E Lifesciences the exclusive rights to therapeutics known as a p38a kinase inhibitor program. The Palo Alto, California-based company is initially developing the compounds to treat for acute respiratory distress syndrome (ARDS), which is a severe lung condition that occurs when too much fluid fills the lungs. ARDS kills 40% of the people that contract it, and there is currently no treatment that has been approved by the U.S. Food and Drug Administration. Going forward, the company believes the treatment could be applied to other types of diseases.

Click here to read the entire article via baltimore